DOCSLIB.ORG

WO 2012/089768 Al 5 July 2012 (05.07.2012) P O P C T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2012/089768 Al 5 July 2012 (05.07.2012) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/089768 Al 5 July 2012 (05.07.2012) P O P C T (51) International Patent Classification: (74) Agent: CARPINTERO LOPEZ, Francisco; Herrero & A61K 47/48 (2006.01) A61P 35/00 (2006.01) Asociados, S.L., Alcala, 35, E-280014 Madrid (ES). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/EP20 11/074150 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 28 December 201 1 (28. 12.201 1) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, P201031 971 28 December 2010 (28. 12.2010) ES SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US): ENDOR NANOTECHNOLOGIES, S.L. [ES/ES]; Edificio Helix - (84) Designated States (unless otherwise indicated, for every c/ Baldiri Reixac, 15, E-08028 Barcelona (ES). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (72) Inventors; and UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, (75) Inventors/Applicants (for US only): VIVERO SANC¬ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, HEZ, Laura [ES/ES]; Edificio Helix, c/ Baldiri Reixac, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 15, E-08028 Barcelona (ES). SENDRA CUADAL, Judith LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, [ES/ES]; Edificio Helix, c/ Baldiri Reixac, 15, E-08028 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Barcelona (ES). PARKKOLA, Hanna [FI/ES]; Edificio GW, ML, MR, NE, SN, TD, TG). Helix, c/ Baldiri Reixac, 15, E-08028 Barcelona (ES). QUEROL SASTRE, Joaquin [ES/ES]; Edificio Helix, c/ Published: Baldiri Reixac, 15, E-08028 Barcelona (ES). RAMIS — with international search report (Art. 21(3)) CASTELLTORT, Marc [ES/ES]; Edificio Helix, c/ Baldiri Reixac, 15, E-08028 Barcelona (ES). (54) Title: SYSTEM FOR THE RELEASE OF A THERAPEUTIC AGENT, PHARMACEUTICAL COMPOSITIONS CONTAIN ING IT, THE PREPARATION AND MEDICAL USE THEREOF - .. ύ ~ 00 HO 00 © FIG. 1 o (57) Abstract: The present invention describes a new system for the selective and controlled release of a therapeutic agent compris - ing: (i) a carrier comprising: a) a metal nanoparticle and b) a hydrophilic HA coating bound to the metal nanoparticle through at least a first ligand, and (ii) at least one therapeutic agent bound to the nanoparticle, to the HA or encapsulated in the HA coating. The in o vention also describes pharmaceutical compositions containing the system for release, their use in the treatment of diseases such as cancer and a method for obtaining them. SYSTEM FOR THE RELEASE OF A THERAPEUTIC AGENT. PHARMACEUTICAL COMPOSITIONS CONTAINING IT, THE PREPARATION AND MEDICAL USE THEREOF Field of the Invention The present invention relates to a new system for the selective and controlled release of a therapeutic agent, comprising a metal nanoparticle, hyaluronic acid and a therapeutic agent. The invention also relates to compositions containing it and to the use of said system and said compositions in therapeutic treatments. Background of the Invention Therapeutic agents administered to the human or animal body are distributed throughout the organism according to their physicochemical properties. The therapeutic agents used today in general do not have specific properties for acting selectively on the selected cells targeted for treatment. These agents therefore randomly affect the cells of the organism, including both the selected cells targeted for application as well as different types of cells not targeted for medical application, causing unwanted side effects. Today, the development of new systems for the controlled and selective release of therapeutic agents is a technological and scientific field in which there is a great deal of activity. The objective of a system for release is to make the desired amount of the therapeutic agent reach the selected cells to obtain a desired therapeutic effect, thereby minimizing the unwanted exposure of the rest of the organism to the agent. In order for the necessary amount to be the minimum amount possible and at the same time therapeutically effective, it is desirable for the system for release to improve the effectiveness of the therapeutic agent. In particular, many therapeutic agents used today, for example in oncological treatments, are specific at the molecular level but not at the cellular level. Therefore, in some cases only a small fraction of the agent reaches the tumor, whereas the rest acts in other tissues of the organism or, in other cases, it is rapidly eliminated from the organism before it can produce any effect in the target tissues, or in contrast, it has a high circulation time and can act in other tissues of the organism causing unwanted effects. A property that systems for the release of therapeutic agents must have is remaining the necessary time in the circulatory system to passively and with the highest probability possible access the target cells. However, if the system for release is not suitably protected, the phagocytic cells of the mononuclear phagocyte system (MPS) can rapidly eliminate it. One of the most widely used techniques for protecting the system for release against the MPS is to coat it with a type of hydrophilic agent that provides it with an aqueous coating that protects it. The components making up the system for release, including the therapeutic agent, are protected and less susceptible to being internalized by the cells of the MPS, which results in a longer blood circulation time. An example of a widely used hydrophilic agent is the polyethylene glycol (PEG). Furthermore, a system for the release of a therapeutic agent must exert a selective action on the target cells. In this sense, in order to direct the system for release to a target cell of the organism it is necessary to have molecules with an affinity for said target cell. Specifically, some monoclonal antibodies recognizing tumor markers are used in the case of tumors due to their capacity to be selectively bound to tumor cells (for example Herceptin (trastuzumab) is a widely used antibody in breast cancer). Binding the antibody that performs vector functions to the system for release can provide it with selectivity but it is still necessary to protect the system for release to prevent it from being internalized by cells of the MPS. Therefore, in order for a system for release to be effective it is desirable for it to have this dual protection and selectivity functionality. Specifically, the system for release must be made up of a hydrophilic agent (for example, PEG) to remain in the blood for the necessary time and a vector molecule conferring selectivity (for example, a monoclonal antibody) and selectively releasing the agent on the target cells. In many cases, the hydrophilic agent and the vector molecule interfere in their functions such that both the hydrophilic capacity and the selectivity of the system for release are lost. This effect limits the application of these systems and in many cases it is necessary to choose between a high blood circulation time or optimal selectivity on the target cells. One way to solve this problem is to have a system for release made up of a single molecule that performs the protection and selectivity functions. Said molecule must keep the system with the agent protected while it is circulating throughout the organism and until it is released in the target cells; it must reach the target cells in the shortest circulation time possible such that the system for release does not circulate more time than that necessary, causing unwanted side effects and its accumulation in other organs. Furthermore, said molecule must have optimal affinity and selectivity in order to be internalized into target cells such that it can perform vector functions. Finally, the release of the therapeutic agent by the system for release is a decisive factor for determining the effectiveness of the system. The objective in this case is for the system to stably conserve the agent until reaching the target cell and once there, to release it without the molecular structure of the agent being altered. Diverse strategies have been designed in the last decade for controlling the kinetics and release of agents. One of the most widespread strategies is the use of liposomes synthesized from biodegradable materials which store the therapeutic agent therein and, as they degrade, gradually release the agent. In order for a system for release made up of liposomes to be effective it must also include a hydrophilic agent protecting against the MPS on the surface of the liposome and a vector molecule which preferably directs the agent to the cells targeted for treatment. Such systems for release have several drawbacks such as the progressive uncontrolled degradation of the liposome in biological medium, making the agent be gradually released as the liposome degrades, compromising the arrival and the release of the agent in the target cell.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,999,632 B2 Falcon Et Al
    US008.999632B2 (12) United States Patent (10) Patent No.: US 8,999,632 B2 Falcon et al. (45) Date of Patent: Apr. 7, 2015 (54) METHOD FOR MEASURING ATR (52) U.S. Cl. INHIBITION MEDIATED INCREASES IN DNA CPC ............ G0IN33/5047 (2013.01); G0IN33/68 DAMAGE (2013.01) (58) Field of Classification Search (71) Applicants: Vertex Pharmaceuticals Incorporated, USPC ........................................................ 435/2, 15 Cambridge, MA (US); University of See application file for complete search history. Newcastle Upon Tyne, Newcastle Upon Tyne (GB) (56) References Cited (72) Inventors: Susanna Falcon, Newbury (GB); Philip PUBLICATIONS Reaper, Shillingford (GB); John Kao et al. Inhibition of Gamma-H2AXAfter Ionizing Radiation. As a Pollard, Abingdon (GB); Nicola Curtin, Biological Surrogate of Impaired Upstream DNA Damage Signaling Newcastle upon Tyne (GB); Fiona and Radiosensitivity; Journal of Cancer Molecules, vol. 5, No. 2 Middleton, South Gosforth (GB); Tao (2010) pp. 49-54.* Chen, Suzhou (CN) Buscemi, G., et al., “DNA Damage-Induced Cell Cycle Regulation of Novel Chk2 Phosphoresidues'. Molecular and Cellular Biology, (73) Assignee: Vertex Pharmaceuticals Incorporated, 26(21), (2006), pp. 7832-7845 (DOI: 10.1128/MCB.00534-06). Boston, MA (US) Chen, T., et al., “Targeting the S and G2 checkpoint to treat cancer. s Drug Discovery Today, 17(5/6), (2012), pp. 194-202, (DOI: 10.1016/ - r - j.drudis.2011, 12.009). (*) Notice: Subject to any disclaimer, the term of this Chen, T., et al., “Development of a biomarker of ATR activity in patent is extended or adjusted under 35 surrogate human tissues”, Newcastle University, Poster, Nov. 2012. U.S.C. 154(b) by 0 days.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Ep 2569287 B1
    (19) TZZ _T (11) EP 2 569 287 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 413/04 (2006.01) C07D 239/46 (2006.01) 09.07.2014 Bulletin 2014/28 (86) International application number: (21) Application number: 11731562.2 PCT/US2011/036245 (22) Date of filing: 12.05.2011 (87) International publication number: WO 2011/143425 (17.11.2011 Gazette 2011/46) (54) COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERBINDUNGEN ALS HEMMER DER ATR-KINASE COMPOSÉS UTILISABLES EN TANT QU’INHIBITEURS DE LA KINASE ATR (84) Designated Contracting States: • VIRANI, Aniza, Nizarali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Abingdon GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Oxfordshire OX144RY (GB) PL PT RO RS SE SI SK SM TR • REAPER, Philip, Michael Abingdon (30) Priority: 12.05.2010 US 333869 P Oxfordshire OX144RY (GB) (43) Date of publication of application: (74) Representative: Coles, Andrea Birgit et al 20.03.2013 Bulletin 2013/12 Kilburn & Strode LLP 20 Red Lion Street (73) Proprietor: Vertex Pharmaceuticals Inc. London WC1R 4PJ (GB) Boston, MA 02210 (US) (56) References cited: (72) Inventors: WO-A1-2010/054398 WO-A1-2010/071837 • CHARRIER, Jean-Damien Abingdon • C. A. HALL-JACKSON: "ATR is a caffeine- Oxfordshire OX144RY (GB) sensitive, DNA-activated protein kinase with a • DURRANT, Steven, John substrate specificity distinct from DNA-PK", Abingdon ONCOGENE, vol. 18, 1999, pages 6707-6713, Oxfordshire OX144RY (GB) XP002665425, cited in the application • KNEGTEL, Ronald, Marcellus Alphonsus Abingdon Oxfordshire OX144RY (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • WO 2015/006592 Al 15 January 2015 (15.01.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/006592 Al 15 January 2015 (15.01.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 401/14 (2006.01) C07D 417/12 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 401/04' (2006.01) C07D 417/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07D 401/12 (2006.01) C07D 251/18 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07D 403/12 (2006.01) A61K 31/53 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07D 403/04' (2006.01) A61P 35/00 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, C07D 413/12 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 14/046204 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 10 July 2014 (10.07.2014) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/845,352 11 July 2013 ( 11.07.2013) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, FT, LT, LU, LV, (71) Applicant: AGIOS PHARMACEUTICALS, INC.
    [Show full text]
  • Section B Changed Classes/Guidelines Final
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2019 Section B Changed Classes/Guidelines Final Version Date of issue: 24th December 2018 1 A3 FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS R2003 A3A PLAIN ANTISPASMODICS AND ANTICHOLINERGICS R1993 Includes all plain synthetic and natural antispasmodics and anticholinergics. A3B Out of use; can be reused. A3C ANTISPASMODIC/ATARACTIC COMBINATIONS This group includes combinations with tranquillisers, meprobamate and/or barbiturates except when they are indicated for disorders of the autonomic nervous system and neurasthenia, in which case they are classified in N5B4. A3D ANTISPASMODIC/ANALGESIC COMBINATIONS R1997 This group includes combinations with analgesics. Products also containing either tranquillisers or barbiturates and analgesics to be also classified in this group. Antispasmodics indicated exclusively for dysmenorrhoea are classified in G2X1. A3E ANTISPASMODICS COMBINED WITH OTHER PRODUCTS r2011 Includes all other combinations not specified in A3C, A3D and A3F. Combinations of antispasmodics and antacids are classified in A2A3; antispasmodics with antiulcerants are classified in A2B9. Combinations of antispasmodics with antiflatulents are classified here. A3F GASTROPROKINETICS r2013 This group includes products used for dyspepsia and gastro-oesophageal reflux. Compounds included are: alizapride, bromopride, cisapride, clebopride, cinitapride, domperidone, levosulpiride, metoclopramide, trimebutine. Prucalopride is classified in A6A9. Combinations of gastroprokinetics with other substances
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Nitrile SKIN2 DECOUVREZ VOTRE 2Ième PEAU
    NITRILE SKIN2 DECOUVREZ VOTRE 2IÈME PEAU PROTECTION CONTRE LES INFECTIONS – imperméable aux virus pour l’utilisateur et le patient EXCELLENTE SENSIBILITE TACTILE – grâce à une épaisseur optimisée PORT TRES CONFORTABLE – grâce au matériau souple novateur tre les on inf t très c c e or on n nte sen c P fo e si ti xemp r io ll b o E t d t t e il n e a c c i b t s l x é e a l e t E t t e o a x r c t n P i l a e t u r e l nitrile skin 2 EXAMINATION GLOVES BY SEMPERMED INFORMATION PRODUITS PROTECTION GANTS 8/3/2012 8/3/2012 RecommandationsRecommandations à propos de la résistance à proposINFORMATIONS aux de la résistance Sempermed® aux produits chimiquesproduits chimiques «Manipulation de produits chimiques en milieu hospitalier avec les gants nitrile Sempercare® 08/03/2012 Les gants de protection àLes usage gants unique de protectionSempercare® à usageont uniqueété contrôlés Sempercare® ont été contrôlés conformémentRecommandations aux exigences à propos deconformément la denorme la résistance EN aux 374-3 exigences aux « produits détermination de chimiques la norme de laEN résistance 374-3 « détermination de la résistance à la perméationLes gants par de desprotection produits àà usage la chimiques perméation unique Sempercare®». par des produits ont été contrôlés chimiques conformément ». aux exigences de la norme EN 374-3 « détermination de la résistance à la perméation par des produits chimiques ». Sempercare® Sempercare® Sempercare® Sempercare® Produit chimique Sempercare®Produit chimique Sempercare® Sempercare® Sempercare® Latex sans
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]
  • FIGURE 1 Human Subjects with Bispecific Anti-CD 123 X Anti-CD3 Antibodies
    ( (51) International Patent Classification: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, A61K 39/395 (2006.01) A61P 35/02 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. A61P 35/00 (2006.01) C07K 16/28 (2006.01) (84) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of regional protection available) . ARIPO (BW, GH, PCT/US20 19/035203 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (22) International Filing Date: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 03 June 2019 (03.06.2019) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (25) Filing Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, (26) Publication Language: English KM, ML, MR, NE, SN, TD, TG). (30) Priority Data: 62/679,25 1 0 1 June 2018 (01.06.2018) US Published: 62/713,439 0 1 August 2018 (01.08.2018) US — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the (71) Applicant: XENCOR, INC. [US/US]; 111 West Lemon claims and to be republished in the event of receipt of Avenue, Monrovia, CA 91016 (US). amendments (Rule 48.2(h)) (72) Inventors: SAVILLE, Michael, Wayne; d o Xencor, Inc., — with sequence listing part of description (Rule 5.2(a)) I l l West Lemon Avenue, Monrovia, CA 91016 (US).
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]